143 related articles for article (PubMed ID: 27786349)
1. CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma.
Ito A; Sugita K; Adachi K; Hosoda Y; Motokura T; Yamamoto O
Acta Derm Venereol; 2017 Mar; 97(3):377-378. PubMed ID: 27786349
[No Abstract] [Full Text] [Related]
2. CD8+ T cell-mediated interface dermatitis during combination chemotherapy with mogamulizumab in a patient with adult T-cell leukaemia/lymphoma.
Tani N; Sugita K; Ito A; Ooi S; Yamamoto O
Clin Exp Dermatol; 2018 Aug; 43(6):736-737. PubMed ID: 29744911
[No Abstract] [Full Text] [Related]
3. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab-induced toxicoderma-like eruptions and autoimmune hepatitis successfully treated with azathioprine in adult T-cell leukaemia/lymphoma.
Nishizawa A; Ishikawa T; Hirose M; Satoh H; Nishii S; Tomita K; Hokari R; Satoh T
Eur J Dermatol; 2017 Dec; 27(6):651-652. PubMed ID: 28739547
[No Abstract] [Full Text] [Related]
5. Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms.
Masuda Y; Tatsuno K; Kitano S; Miyazawa H; Ishibe J; Aoshima M; Shimauchi T; Fujiyama T; Ito T; Tokura Y
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1456-1460. PubMed ID: 29341283
[TBL] [Abstract][Full Text] [Related]
6. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
Kanno K; Honma M; Ishida-Yamamoto A
J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
[No Abstract] [Full Text] [Related]
9. Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma.
Yonekura K; Tokunaga M; Kawakami N; Takeda K; Kanzaki T; Nakano N; Kubota A; Takeuchi S; Takatsuka Y; Seto M; Utsunomiya A
Acta Derm Venereol; 2016 Nov; 96(7):1000-1002. PubMed ID: 27025906
[No Abstract] [Full Text] [Related]
10. Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.
Honda T; Hishizawa M; Kataoka TR; Ohmori K; Takaori-Kondo A; Miyachi Y; Kabashima K
Acta Derm Venereol; 2015 May; 95(5):606-7. PubMed ID: 25424342
[No Abstract] [Full Text] [Related]
11. Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia.
Mohammed TO; Chagan-Yasutan H; Ashino Y; Nakayama W; Takahashi Y; Shimomura T; Fujimoto T; Watanabe Y; Niki T; Suzushima H; Hattori T
Tohoku J Exp Med; 2017 Mar; 241(3):201-208. PubMed ID: 28321034
[TBL] [Abstract][Full Text] [Related]
12. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
Iida S; Ishida T; Ueda R
Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
[TBL] [Abstract][Full Text] [Related]
13. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
14. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
[No Abstract] [Full Text] [Related]
15. Depletion of central memory CD8
Maeda Y; Wada H; Sugiyama D; Saito T; Irie T; Itahashi K; Minoura K; Suzuki S; Kojima T; Kakimi K; Nakajima J; Funakoshi T; Iida S; Oka M; Shimamura T; Doi T; Doki Y; Nakayama E; Ueda R; Nishikawa H
Nat Commun; 2021 Dec; 12(1):7280. PubMed ID: 34907192
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient.
Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y
Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968
[No Abstract] [Full Text] [Related]
17. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy.
Yamauchi J; Coler-Reilly A; Sato T; Araya N; Yagishita N; Ando H; Kunitomo Y; Takahashi K; Tanaka Y; Shibagaki Y; Nishioka K; Nakajima T; Hasegawa Y; Utsunomiya A; Kimura K; Yamano Y
J Infect Dis; 2015 Jan; 211(2):238-48. PubMed ID: 25104771
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
[TBL] [Abstract][Full Text] [Related]
20. Emergence of Photosensitivity with Decreased Treg Cells in a Patient with Mycosis Fungoides Treated with Anti-CC Chemokine Receptor 4 Antibody Mogamulizumab.
Tatsuno K; Sano T; Fukuchi K; Kuriyama S; Aoshima M; Kasuya A; Ikeya S; Fujiyama T; Ito T; Tokura Y
Acta Derm Venereol; 2016 Mar; 96(3):420-1. PubMed ID: 26463269
[No Abstract] [Full Text] [Related]
[Next] [New Search]